Embedded Files
As we move past the December stock slump, investors are increasingly looking for attractive stocks to invest in. We decided to profile two companies that caught our attention:
ChromaDex Corp (NASDAQ: CDXC)
ChromaDex Corp (NASDAQ: CDXC)
ChromaDex is a company specialized in the production of nicotinamide riboside (NR), a nutritional supplement with presumed life-prolonging effect. The supplement is marketed as Niagen Tru, and has seen its sales grow in the past year as more research comes out on the topic. A search on ClinicalTrials.gov turns up many studies currently investigating NR. Everything from kidney disease to mitochondrial biogenesis.
With an ageing population, interest in anything that prolongs life or makes you younger will receive significant interest. With a big number of trials underway and some on the way to report their findings, the stock (currently ~$3-4) has the potential to be a winner with the right results.
Harrow Health (NASDAQ: HROW)
Harrow Health (NASDAQ: HROW)
Harrow Health (previously ImprimisRx), a speciality compounding pharmaceutical company, has quickly grown in the past year, buoyed by sales of its ophthalmology products. It has deconsolidated two of its most successful divisions, the ophthalmology division as well as MELT while retaining significant shares in both. As their sales grow, and they market MKO MELT (which could potentially change the way cataract surgery is done), their shares are likely to be boosted. The goal, named Project 15, aims to raise the share price to $15 (currently at ~$5). With the right market conditions and the right products, they are likely to reach that target within a year or two, giving you a handsome 200-300% return on the investment.
------------------------------------------------------
Disclaimer: Please remember that past performance may not be indicative of future results. Different types of investments involve varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this post, will be profitable, equal any corresponding indicated historical performance level(s), or be suitable for your portfolio. Due to various factors, including changing market conditions, the content may no longer be reflective of current opinions or positions. Conflict of interest may arise as the authors may have shares in the companies above. You should not assume that any discussion or information contained in this post serves as the receipt of, or as a substitute for, personalized investment advice from CCIR. To the extent that a reader has any questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional advisor of his/her choosing.
Google Sites
Report abuse